Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01244191
Show Display Options
Rank Status Study
1 Active, not recruiting ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Condition: Non Squamous, Non-small-cell Lung Cancer
Interventions: Drug: Tivantinib (ARQ 197);   Drug: ARQ 197 placebo;   Drug: Erlotinib

Indicates status has not been verified in more than two years